biokangtai.comCrawled Nov 21, 2026
The vaccine comes in two formats: pre-filled syringes and West-style vials, developed under the National Science and Technology Support Program.
The company developed China’s first domestically produced four-valent vaccine as part of the national '863 Program'.
The company was the first to undertake the introduction and production of recombinant hepatitis B vaccine technology.
Shenzhen CanSino Biologics was founded in 1992 and specializes in vaccine research, production, and sales. It listed on the Shenzhen Stock Exchange in February 2017 (stock code: 300601) as the first vaccine company to go public in South China.
Shenzhen Kangtai Biological Products begins Phase I trials of its domestically developed DTaP combination vaccine, targeting adults, adolescents, and children. The adsorbed acellular vaccine marks China’s first such candidate in development, with no approved equivalent from domestic manufacturers. The trial successfully enrolled its first participant through its subsidiary, Beijing Minhai Biological Technology.
Shenzhen Kangtai Biological Products is seizing opportunities in vaccine manufacturing by collaborating with developing nations seeking to establish their own production capabilities. The company’s international business unit highlights rising demand for localized vaccine production as a key growth area.
Shenzhen Kangtai Biological Products Co. (SHE: 300601) begins a Phase I clinical trial for its trivalent influenza split vaccine, produced in MDCK cells. The study, single-center and randomized, assesses safety and preliminary immune response in participants aged 3 and older. The vaccine targets protection against matched influenza virus strains.
Shenzhen Kangtai Biological Products Co. Ltd. co-founded the **Beijing Key Laboratory of Synthetic Immunology and Vaccine Intelligent Manufacturing** with the **Chinese Academy of Sciences (CAS)**, Xinzhi Bio, and Liaoning Cheng Da Biotechnology. The lab focuses on advancing **antigen design, adjuvant development, and intelligent vaccine production** to drive innovation in synthetic immunology. Minhai Biotechnology, a Kangtai subsidiary, leads the collaboration alongside academic and industry partners.
Shenzhen Kangtai Biological Products acquires a Klebsiella pneumoniae pneumonia vaccine from Professor Zou Quanming’s team at Army Medical University for **530 million yuan** in milestone-based payments. The technology-transfer agreement grants Kangtai rights to develop and commercialize the vaccine, with the first payment tied to predefined development milestones. The deal expands Kangtai’s portfolio in respiratory infectious disease treatments.
Shenzhen Kangtai Biological Products collaborates with Gennvax Egypt to commercialize its 13-valent pneumococcal polysaccharide conjugate vaccine. The partnership aims to secure marketing approval in Egypt and establish local raw material production. The agreement includes agency and technology transfer components to support vaccine distribution and manufacturing.
AstraZeneca, Combiphar, and BioKangtai have signed a Memorandum of Understanding to collaborate on vaccine development in Indonesia. The partnership aims to enhance vaccine cooperation between Indonesia and China while improving Indonesia’s manufacturing resilience and access to medicines. The agreement focuses on strengthening local production capabilities and regional healthcare infrastructure.